Novel contrast agents and biomarkers from preclinical to clinical applications
An image for health
Since the late 1800s imaging technologies have been utilized to non-invasively, visualize samples or tissues using a variety of wave sources. Today medical imaging technologies are widely used in clinical diagnosis to guide therapeutic and surgical intervention, to monitor disease progression, recurrence and treatment response and to improve surgical navigation. One of the driving forces for novel imaging diagnostic tools is the shift in demographics. With an aging population chronic diseases such as diabetes, chronic obstructive pulmonary disease, and Alzheimer’s are on the rise. These long-term degenerative diseases place a high cost burden on the healthcare systems. The sooner doctors can detect, treat, and/or prevent these conditions in patients, the more they can reduce this burden.
Medical imaging can contribute to better overall patient care by:
• personalized medicine with individually tailored treatment
• more evidence-based decision making within healthcare
• less complications during and after surgery
• better understanding of the effect of treatments on diseases
Clinical use is obviously one major driving force behind the development of novel medical imaging, yet another important driver is the use of medical imaging early on in preclinical development of new drugs and companion diagnostics. Methods that can improve drug development in an early phase will have a major impact on success rate and reduce costs during the long and costly drug development process. A translational approach during drug development can further bridge the gap between preclinical research and clinical development of companion diagnostics.
– see more clearly with novel contrast agents and biomarkers
GeccoDots provides unique multimodal contrast agents and biomarkers for medical imaging. By combining contrast agents, optical probes, radionuclides and nanotechnology, GeccoDots products offer a new toolbox for multipurpose imaging. The toolbox allows users to mix and match, such as combining MRI, PET and ultrasound in preclinical imaging using one and the same agent. GeccoDots envisions a translational approach; for example, near-IR imaging can be combined with PET to allow diagnostic screening and intraoperative guidance using a single agent. The ready-to-use products are available in convenient kits, as well as in customized formats. The multimodal imaging agents for preclinical use is GeccoDots first product line, which the company markets within the medical imaging business in order to reach key opinion leaders, reference groups and to make the business aware of the company portfolio. The preclinical business is developed strategically to become a self-sufficient communication platform used to establish relationships with key partners for the commercialization of the clinical projects within GeccoDots.
Please, visit GeccoDots web site for more information on our preclinical products, www.geccodots.com!
Clinical project in pipeline:
Nanoparticles in motion gives great contrast in ultrasound imaging
Since 2013, GeccoDots has together with a team of scientists specialized in ultrasound technology, radiology and surgery at Lund University and Lund University Hospital focused on the continued development of a new nanosized multimodal contrast agents for ultrasound and PET imaging, the Nanomotus project, and has shown proof-of-concept in preclinical animal models.
The Nanomotus method is based on setting nanostructures in motion and at the same time detect this movement using ultrasound. The technology includes hardware in terms of a small device generating a magnetic field, software, and a contrast agent based on multimodal nanostructures. The first goal in terms of clinical indications is the detection of lymph nodes in applications associated with staging, surgery and diagnosis of malignant diseases. Other applications such as image guided prostate biopsy exams and monitoring of the progression and treatment of atherosclerotic plaque will be further evaluated as future target indications for the Nanomotus technology.
The first picture shows the ultrasound image of an animal model in an area close to a lymph node (the node is here indicated with a with line). The nanostructures have been injected subcutaneously and the lymph node is expected to drain the injection site. In picture two, the image shows the total movements of the nanoparticles and the background in red. In the final image the specific movement originating from the nanoparticles is extracted after analyzing the ultrasound signal using designated software and the lymph node is clearly identified as the node carrying nanostructures, hence a sentinel lymph node.